Christel C. Herold‐mende

Christel C. Herold‐mende's AcademicInfluence.com Rankings

Medical

#3477

World Rank

#3946

Historical Rank

Oncology

#243

World Rank

#251

Historical Rank

medical Degrees

Christel C. Herold‐mende

Biology

#13703

World Rank

#17259

Historical Rank

Computational Biology

#322

World Rank

#323

Historical Rank

biology Degrees

Download Badge

Medical
Biology

Why Is Christel C. Herold‐mende Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Christel C. Herold‐mende's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. (2015) (2211)
Oncogenic Signaling Pathways in The Cancer Genome Atlas (2018) (1646)
Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. (2012) (1532)
DNA methylation-based classification of central nervous system tumours (2018) (1461)
Comprehensive Characterization of Cancer Driver Genes and Mutations (2018) (1360)
Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas (2009) (1062)
Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma (2011) (871)
Dissecting the genomic complexity underlying medulloblastoma (2012) (777)
The whole-genome landscape of medulloblastoma subtypes (2017) (658)
Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma (2013) (637)
Stem Cell Marker CD133 Affects Clinical Outcome in Glioma Patients (2008) (615)
New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs (2016) (608)
Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition. (2014) (601)
Pathogenic Germline Variants in 10,389 Adult Cancers (2018) (501)
Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. (2015) (486)
Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients (2018) (471)
BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. (2008) (456)
DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. (2017) (447)
Expression and immunolocalization of the multidrug resistance proteins, MRP1–MRP6 (ABCC1–ABCC6), in human brain (2004) (372)
ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an “integrated” diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma (2014) (367)
BCAT1 promotes cell proliferation through amino acid catabolism in gliomas carrying wild-type IDH1 (2013) (347)
Yes and PI3K bind CD95 to signal invasion of glioblastoma. (2008) (315)
Differentiation Therapy Exerts Antitumor Effects on Stem-like Glioma Cells (2010) (306)
Stem cell-associated heterogeneity in Glioblastoma results from intrinsic tumor plasticity shaped by the microenvironment (2019) (306)
Meningeal hemangiopericytoma and solitary fibrous tumors carry the NAB2-STAT6 fusion and can be diagnosed by nuclear expression of STAT6 protein (2013) (292)
ABCC drug efflux pumps and organic anion uptake transporters in human gliomas and the blood-tumor barrier. (2005) (286)
Effector T-Cell Infiltration Positively Impacts Survival of Glioblastoma Patients and Is Impaired by Tumor-Derived TGF-β (2011) (266)
Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate (2018) (264)
TERT Promoter Mutations and Risk of Recurrence in Meningioma. (2016) (259)
Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system (2013) (254)
Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas (2017) (253)
Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma (2014) (243)
IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO (2015) (241)
Novel, improved grading system(s) for IDH-mutant astrocytic gliomas (2018) (236)
Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities (2015) (230)
Long noncoding RNA TARID directs demethylation and activation of the tumor suppressor TCF21 via GADD45A. (2014) (230)
Radiogenomics of Glioblastoma: Machine Learning-based Classification of Molecular Characteristics by Using Multiparametric and Multiregional MR Imaging Features. (2016) (221)
Expression of mutated p53 occurs in tumor-distant epithelia of head and neck cancer patients: a possible molecular basis for the development of multiple tumors. (1993) (211)
Antitumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety, and clinical benefit. (2004) (202)
Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins (2008) (201)
When Immune Cells Turn Bad—Tumor-Associated Microglia/Macrophages in Glioma (2018) (194)
Secretory meningiomas are defined by combined KLF4 K409Q and TRAF7 mutations (2013) (194)
Next-generation sequencing in routine brain tumor diagnostics enables an integrated diagnosis and identifies actionable targets (2016) (188)
Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context (2018) (188)
Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma (2014) (180)
Clinical impact and functional aspects of tenascin‐C expression during glioma progression (2002) (169)
Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy. (2012) (165)
Genomic and Expression Profiling of Glioblastoma Stem Cell–Like Spheroid Cultures Identifies Novel Tumor-Relevant Genes Associated with Survival (2009) (160)
Recurrent MET fusion genes represent a drug target in pediatric glioblastoma (2016) (160)
Undressing of phosphine gold(I) complexes as irreversible inhibitors of human disulfide reductases. (2006) (156)
De-repression of CTGF via the miR-17-92 cluster upon differentiation of human glioblastoma spheroid cultures (2010) (155)
Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma (2018) (154)
Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A/B and ATRX alterations (2018) (154)
Radiomic subtyping improves disease stratification beyond key molecular, clinical, and standard imaging characteristics in patients with glioblastoma (2018) (149)
Histologically distinct neuroepithelial tumors with histone 3 G34 mutation are molecularly similar and comprise a single nosologic entity (2015) (145)
CIC and FUBP1 mutations in oligodendrogliomas, oligoastrocytomas and astrocytomas (2012) (144)
Evolutionary Trajectories of IDHWT Glioblastomas Reveal a Common Path of Early Tumorigenesis Instigated Years ahead of Initial Diagnosis. (2019) (138)
Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo (2017) (135)
Autocrine growth regulation by granulocyte colony-stimulating factor and granulocyte macrophage colony-stimulating factor in human gliomas with tumor progression. (1999) (134)
Different angiogenic phenotypes in primary and secondary glioblastomas (2006) (134)
Human thioredoxin reductase is efficiently inhibited by (2,2':6',2' '-terpyridine)platinum(II) complexes. Possible implications for a novel antitumor strategy. (2001) (131)
Expression profiles of angiogenic growth factors in squamous cell carcinomas of the head and neck (2003) (131)
RNAi screening in glioma stem-like cells identifies PFKFB4 as a key molecule important for cancer cell survival (2012) (129)
DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management. (2019) (128)
DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management. (2019) (128)
Methylation-based classification of benign and malignant peripheral nerve sheath tumors (2016) (126)
The chromatin remodeler CHD7 regulates adult neurogenesis via activation of SoxC transcription factors. (2013) (125)
Expression and functional significance of vascular endothelial growth factor receptors in human tumor cells. (1999) (118)
Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor promote malignant growth of cells from head and neck squamous cell carcinomas in vivo. (2006) (114)
Immunization with virus-modified tumor cells. (1998) (111)
Specific elimination of CD133+ tumor cells with targeted oncolytic measles virus. (2013) (104)
Glioma through the looking GLASS: molecular evolution of diffuse gliomas and the Glioma Longitudinal Analysis Consortium (2018) (102)
Antitumor Vaccination in Patients with Head and Neck Squamous Cell Carcinomas with Autologous Virus-Modified Tumor Cells (2004) (101)
Bone morphogenetic protein-7 release from endogenous neural precursor cells suppresses the tumourigenicity of stem-like glioblastoma cells. (2010) (95)
Comprehensive Analysis of Glycolytic Enzymes as Therapeutic Targets in the Treatment of Glioblastoma (2015) (94)
Acyl-CoA-Binding Protein Drives Glioblastoma Tumorigenesis by Sustaining Fatty Acid Oxidation. (2019) (94)
Loss of histone H3K27me3 identifies a subset of meningiomas with increased risk of recurrence (2018) (94)
Glycolysis and the pentose phosphate pathway are differentially associated with the dichotomous regulation of glioblastoma cell migration versus proliferation. (2015) (94)
EXPRESSION OF CD44 SPLICE VARIANTS IN SQUAMOUS EPITHELIA AND SQUAMOUS CELL CARCINOMAS OF THE HEAD AND NECK (1996) (94)
Novel Anti-Apoptotic MicroRNAs 582-5p and 363 Promote Human Glioblastoma Stem Cell Survival via Direct Inhibition of Caspase 3, Caspase 9, and Bim (2014) (92)
Stem-cell-like glioma cells are resistant to TRAIL/Apo2L and exhibit down-regulation of caspase-8 by promoter methylation (2009) (91)
LGR5 is a Marker of Poor Prognosis in Glioblastoma and is Required for Survival of Brain Cancer Stem‐Like Cells (2013) (90)
The flavonoid kaempferol sensitizes human glioma cells to TRAIL-mediated apoptosis by proteasomal degradation of survivin (2008) (90)
Chemical approaches to targeting drug resistance in cancer stem cells. (2013) (87)
Autocrine Pathways of the Vascular Endothelial Growth Factor (VEGF) in Glioblastoma Multiforme: Clinical Relevance of Radiation-Induced Increase of VEGF Levels (2004) (86)
The Wnt secretion protein Evi/Gpr177 promotes glioma tumourigenesis (2012) (85)
Human multidrug resistance protein 8 (MRP8/ABCC11), an apical efflux pump for steroid sulfates, is an axonal protein of the CNS and peripheral nervous system (2006) (84)
AKT1E17K mutations cluster with meningothelial and transitional meningiomas and can be detected by SFRP1 immunohistochemistry (2013) (83)
The Utility and Limitations of Neurosphere Assay, CD133 Immunophenotyping and Side Population Assay in Glioma Stem Cell Research (2010) (83)
Noninvasive positron emission tomography and fluorescence imaging of CD133+ tumor stem cells (2014) (82)
Expression of facilitative glucose transport proteins during development of squamous cell carcinomas of the head and neck (1999) (82)
Basal Caspase Activity Promotes Migration and Invasiveness in Glioblastoma Cells (2007) (81)
Sensitivity and specificity of antibodies against HPV16 E6 and other early proteins for the detection of HPV16‐driven oropharyngeal squamous cell carcinoma (2017) (81)
Microglia isolated from patients with glioma gain antitumor activities on poly (I:C) stimulation. (2012) (79)
N2M2 (NOA-20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma. (2018) (79)
Mechanistic Studies on a Novel, Highly Potent Gold-Phosphole Inhibitor of Human Glutathione Reductase* (2005) (78)
Advances in multidisciplinary therapy for meningiomas. (2019) (77)
CDKN2A/B homozygous deletion is associated with early recurrence in meningiomas (2020) (77)
MYCN amplification drives an aggressive form of spinal ependymoma (2019) (70)
Parvovirus H‐1 infection of human glioma cells leads to complete viral replication and efficient cell killing (2004) (69)
Low Frequency of Chromosomal Imbalances in Anaplastic Ependymomas as Detected by Comparative Genomic Hybridization (2001) (69)
Insight into the complex regulation of CD133 in glioma (2011) (68)
Long-term outcome and survival of surgically treated supratentorial low-grade glioma in adult patients (2009) (67)
Antimalarial versus cytotoxic properties of dual drugs derived from 4-aminoquinolines and Mannich bases: interaction with DNA. (2010) (66)
Molecular crosstalk between tumour and brain parenchyma instructs histopathological features in glioblastoma (2016) (65)
Aberrant expression of retinoic acid signaling molecules influences patient survival in astrocytic gliomas. (2011) (64)
Notch1 signaling promotes survival of glioblastoma cells via EGFR-mediated induction of anti-apoptotic Mcl-1 (2012) (62)
Transmembrane protein CD9 is glioblastoma biomarker, relevant for maintenance of glioblastoma stem cells (2015) (62)
No prognostic value of IDH1 mutations in a series of 100 WHO grade II astrocytomas (2012) (61)
Molecular profiling of long-term survivors identifies a subgroup of glioblastoma characterized by chromosome 19/20 co-gain (2015) (57)
Glutathione peroxidase 1 activity dictates the sensitivity of glioblastoma cells to oxidative stress (2012) (57)
Association of Stem Cell-Related Markers and Survival in Astrocytic Gliomas (2011) (56)
Enzymatic assay for quantitative analysis of (d)-2-hydroxyglutarate (2012) (56)
Integrated molecular characterization of IDH‐mutant glioblastomas (2018) (55)
Comparative analysis of in vitro conditions for rat adult neural progenitor cells (2007) (55)
The PEA-15/PED protein protects glioblastoma cells from glucose deprivation-induced apoptosis via the ERK/MAP kinase pathway (2008) (53)
BRAF V600E analysis for the differentiation of papillary craniopharyngiomas and Rathke's cleft cysts (2015) (53)
Mutational patterns and regulatory networks in epigenetic subgroups of meningioma (2019) (52)
Stem cell characteristics in glioblastoma are maintained by the ecto-nucleotidase E-NPP1 (2014) (52)
Aberrant self‐renewal and quiescence contribute to the aggressiveness of glioblastoma (2014) (52)
Integrated Molecular-Morphologic Meningioma Classification: A Multicenter Retrospective Analysis, Retrospectively and Prospectively Validated (2021) (51)
GPD1 Specifically Marks Dormant Glioma Stem Cells with a Distinct Metabolic Profile. (2019) (51)
Subgroup-specific localization of human medulloblastoma based on pre-operative MRI (2014) (51)
Clonal Analysis in Recurrent Astrocytic, Oligoastrocytic and Oligodendroglial Tumors Implicates IDH1- Mutation as Common Tumor Initiating Event (2012) (50)
Paracrine Effects of Mesenchymal Stem Cells Induce Senescence and Differentiation of Glioblastoma Stem-Like Cells (2015) (49)
Expression of the histone H3 gene in benign, semi-malignant and malignant lesions of the head and neck: a reliable proliferation marker. (1993) (49)
Identification and Characterization of a Peptide with Affinity to Head and Neck Cancer (2009) (48)
NIMG-56IMMUNOTHERAPY RESPONSE ASSESSMENT IN NEURO-ONCOLOGY (iRANO): A REPORT OF THE RANO WORKING GROUP (2015) (47)
Patient-derived organoids and orthotopic xenografts of primary and recurrent gliomas represent relevant patient avatars for precision oncology (2020) (47)
Rosette-forming glioneuronal tumors share a distinct DNA methylation profile and mutations in FGFR1, with recurrent co-mutation of PIK3CA and NF1 (2019) (45)
Heparanase Expression at the Invasion Front of Human Head and Neck Cancers and Correlation with Poor Prognosis (2005) (45)
Targeting APLN/APLNR Improves Antiangiogenic Efficiency and Blunts Proinvasive Side Effects of VEGFA/VEGFR2 Blockade in Glioblastoma. (2019) (45)
Comparative analysis of transcriptomics based hypoxia signatures in head- and neck squamous cell carcinoma. (2016) (45)
Carbon irradiation overcomes glioma radioresistance by eradicating stem cells and forming an antiangiogenic and immunopermissive niche. (2019) (44)
Zeb1 potentiates genome‐wide gene transcription with Lef1 to promote glioblastoma cell invasion (2018) (44)
Defects of basement membrane and hemidesmosome structure correlate with malignant phenotype and stromal interactions in HaCaT-Ras xenografts. (1999) (44)
CD133/prominin1 is prognostic for GBM patient’s survival, but inversely correlated with cysteine cathepsins’ expression in glioblastoma derived spheroids (2011) (43)
FGFR1:TACC1 fusion is a frequent event in molecularly defined extraventricular neurocytoma (2018) (43)
Expression and regulation of AC133 and CD133 in glioblastoma (2011) (43)
Radiosensitivity of Patient-Derived Glioma Stem Cell 3-Dimensional Cultures to Photon, Proton, and Carbon Irradiation. (2016) (42)
Microsatellite Instability in Pediatric and Adult High‐grade Gliomas (2007) (42)
Expression of PD-1 by T Cells in Malignant Glioma Patients Reflects Exhaustion and Activation (2018) (42)
Expression of nuclear receptor corepressors and class I histone deacetylases in astrocytic gliomas (2011) (42)
In vitro responsiveness of glioma cell lines to multimodality treatment with radiotherapy, temozolomide, and epidermal growth factor receptor inhibition with cetuximab. (2007) (41)
Proximity ligation assay evaluates IDH1R132H presentation in gliomas. (2015) (40)
Cell death induction by betulinic acid, ceramide and TRAIL in primary glioblastoma multiforme cells (2004) (40)
Chemotherapy with BCNU in recurrent glioma: Analysis of clinical outcome and side effects in chemotherapy-naïve patients (2016) (39)
Antiglioma activity of 2,2':6',2"-terpyridineplatinum(II) complexes in a rat model--effects on cellular redox metabolism. (2006) (38)
Asymmetric Centriole Numbers at Spindle Poles Cause Chromosome Missegregation in Cancer. (2017) (36)
Reduced promoter methylation and increased expression of CSPG4 negatively influences survival of HNSCC patients (2014) (36)
Unique challenges for glioblastoma immunotherapy - Discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. (2020) (36)
YAP1-fusions in pediatric NF2-wildtype meningioma (2019) (35)
Routine RNA sequencing of formalin-fixed paraffin-embedded specimens in neuropathology diagnostics identifies diagnostically and therapeutically relevant gene fusions (2019) (35)
Transcriptomic analysis of aggressive meningiomas identifies PTTG1 and LEPR as prognostic biomarkers independent of WHO grade (2016) (35)
Angiogenic growth factors in tissue homogenates of HNSCC: expression pattern, prognostic relevance, and interrelationships (2009) (35)
Brainstem biopsy in pediatric diffuse intrinsic pontine glioma in the era of precision medicine: the INFORM study experience. (2019) (34)
Epigenetic screen of human DNA repair genes identifies aberrant promoter methylation of NEIL1 in head and neck squamous cell carcinoma (2012) (34)
Identification of a Novel ITGαvβ6-Binding Peptide Using Protein Separation and Phage Display (2017) (33)
Preclinical drug screen reveals topotecan, actinomycin D, and volasertib as potential new therapeutic candidates for ETMR brain tumor patients (2017) (33)
Diffuse glioneuronal tumour with oligodendroglioma‐like features and nuclear clusters (DGONC) – a molecularly defined glioneuronal CNS tumour class displaying recurrent monosomy 14 (2019) (33)
IDH1 mutations induce organelle defects via dysregulated phospholipids (2020) (32)
The Senescence-associated Secretory Phenotype Mediates Oncogene-induced Senescence in Pediatric Pilocytic Astrocytoma (2018) (32)
Spatial transcriptome analysis reveals Notch pathway-associated prognostic markers in IDH1 wild-type glioblastoma involving the subventricular zone (2016) (32)
Infratentorial IDH-mutant astrocytoma is a distinct subtype (2020) (32)
Identification of a Prognostic Hypoxia-Associated Gene Set in IDH-Mutant Glioma (2018) (31)
Tumors diagnosed as cerebellar glioblastoma comprise distinct molecular entities (2019) (30)
Comparison of the RGD Motif–Containing αvβ6 Integrin–Binding Peptides SFLAP3 and SFITGv6 for Diagnostic Application in HNSCC (2018) (30)
Voxel-wise radiogenomic mapping of tumor location with key molecular alterations in patients with glioma (2018) (30)
Expression and putative functions of GDF-15, a member of the TGF-beta superfamily, in human glioma and glioblastoma cell lines. (2008) (30)
Rapid detection of 2-hydroxyglutarate in frozen sections of IDH mutant tumors by MALDI-TOF mass spectrometry (2018) (30)
Effective Eradication of Glioblastoma Stem Cells by Local Application of an AC133/CD133-Specific T-cell-Engaging Antibody and CD8 T Cells. (2015) (30)
BRAF mutations distinguish anorectal from cutaneous melanoma at the molecular level. (2004) (30)
Antiglioma activity of GoPI-sugar, a novel gold(I)-phosphole inhibitor: chemical synthesis, mechanistic studies, and effectiveness in vivo. (2014) (29)
Discriminating expression of differentiation markers evolves in transplants of benign and malignant human skin keratinocytes through stromal interactions (2003) (29)
Identification of CRKII, CFL1, CNTN1, NME2, and TKT as Novel and Frequent T-Cell Targets in Human IDH-Mutant Glioma (2018) (29)
Metabolic Reprogramming Associated with Aggressiveness Occurs in the G-CIMP-High Molecular Subtypes of IDH1mut Lower Grade Gliomas. (2019) (29)
Combination of thalidomide and cisplatin in an head and neck squamous cell carcinomas model results in an enhanced antiangiogenic activity in vitro and in vivo (2007) (29)
Expansive growth of two glioblastoma stem-like cell lines is mediated by bFGF and not by EGF (2013) (28)
MetaboDiff: an R package for differential metabolomic analysis (2018) (28)
Feasibility of real-time molecular profiling for patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation—the NCT Neuro Master Match (N2M2) pilot study (2018) (27)
Comparison of Extracorporal Shock Wave Pretreatment to Classic Surgical Delay in a Random Pattern Skin Flap Model (2011) (27)
Identification of KIF11 as a Novel Target in Meningioma (2019) (27)
Cytogenetic characterization of head and neck squamous cell carcinoma cell lines as model systems for the functional analyses of tumor-associated genes. (2010) (27)
Targeting atypical protein kinase C iota reduces viability in glioblastoma stem‐like cells via a notch signaling mechanism (2016) (27)
Microscopic brain invasion in meningiomas previously classified as WHO grade I is not associated with patient outcome (2019) (26)
Antigenic expression and spontaneous immune responses support the use of a selected peptide set from the IMA950 glioblastoma vaccine for immunotherapy of grade II and III glioma (2017) (26)
[Cytokine expression of transforming growth factor-beta2 and interleukin-10 in squamous cell carcinomas of the head and neck. Comparison of tissue expression and serum levels]. (1999) (25)
Prognostic value of the extent of resection in supratentorial WHO grade II astrocytomas stratified for IDH1 mutation status: a single-center volumetric analysis (2016) (24)
NKIM-6, a new immortalized human brain capillary endothelial cell line with conserved endothelial characteristics (2007) (24)
A DNA Repair and Cell-Cycle Gene Expression Signature in Primary and Recurrent Glioblastoma: Prognostic Value and Clinical Implications. (2019) (24)
Location-Dependent Patient Outcome and Recurrence Patterns in IDH1-Wildtype Glioblastoma (2019) (24)
Meningiomas induced by low-dose radiation carry structural variants of NF2 and a distinct mutational signature (2017) (23)
Epigenetically mediated downregulation of the differentiation‐promoting chaperon protein CRABP2 in astrocytic gliomas (2012) (23)
Printed peptide arrays identify prognostic TNC serumantibodies in glioblastoma patients (2015) (23)
Evaluation of drug transporters' significance for multidrug resistance in head and neck squamous cell carcinoma (2011) (23)
Clinical and immunological correlates of long term survival in glioblastoma (2018) (22)
Potential Canonical Wnt Pathway Activation in High-Grade Astrocytomas (2012) (22)
T2/FLAIR-mismatch sign for noninvasive detection of IDH-mutant 1p/19q non-codeleted gliomas: validity and pathophysiology (2020) (22)
Association of Drug Transporter Expression with Mortality and Progression-Free Survival in Stage IV Head and Neck Squamous Cell Carcinoma (2014) (22)
Mutant IDH1 Differently Affects Redox State and Metabolism in Glial Cells of Normal and Tumor Origin (2019) (22)
Antitumor immunization of head and neck squamous cell carcinoma patients with a virus-modified autologous tumor cell vaccine. (2005) (22)
Resistance to hypoxia-induced, BNIP3-mediated cell death contributes to an increase in a CD133-positive cell population in human glioblastomas in vitro. (2012) (22)
Cross-species genomics reveals oncogenic dependencies in ZFTA/C11orf95 fusion-positive supratentorial ependymomas. (2021) (22)
Identification of T cell target antigens in glioblastoma stem-like cells using an integrated proteomics-based approach in patient specimens (2017) (21)
Rapid T cell-based identification of human tumor tissue antigens by automated two-dimensional protein fractionation. (2010) (21)
Preoperative shock wave treatment enhances ischemic tissue survival, blood flow and angiogenesis in a rat skin flap model. (2011) (21)
Natural HLA class I ligands from glioblastoma: extending the options for immunotherapy (2013) (21)
Prognostic factors and long-term survival in surgically treated brain metastases from non-small cell lung cancer (2016) (21)
Pediatric and Adult High-Grade Glioma Stem Cell Culture Models Are Permissive to Lytic Infection with Parvovirus H-1 (2016) (20)
Clear cell meningiomas are defined by a highly distinct DNA methylation profile and mutations in SMARCE1 (2020) (20)
Metastatic growth of squamous cell carcinomas is correlated with upregulation and redistribution of hemidesmosomal components (2001) (20)
Intraventricular meningiomas frequently harbor NF2 mutations but lack common genetic alterations in TRAF7, AKT1, SMO, KLF4, PIK3CA, and TERT (2019) (20)
Expression of SGLT-1 in preneoplastic and neoplastic lesions of the head and neck (2004) (20)
Mobile phone specific electromagnetic fields induce transient DNA damage and nucleotide excision repair in serum-deprived human glioblastoma cells (2018) (19)
LOC283731 promoter hypermethylation prognosticates survival after radiochemotherapy in IDH1 wild‐type glioblastoma patients (2016) (19)
PET/CT Imaging of NSCLC with a αvβ6 Integrin-Targeting Peptide (2019) (19)
Tumor specific regulatory T cells in the bone marrow of breast cancer patients selectively upregulate the emigration receptor S1P1 (2017) (18)
Reduced chromatin binding of MYC is a key effect of HDAC inhibition in MYC amplified medulloblastoma. (2020) (17)
FASN Is a Biomarker Enriched in Malignant Glioma-Derived Extracellular Vesicles (2020) (17)
Minor role of pregnane-x-receptor for acquired multidrug resistance in head and neck squamous cell carcinoma in vitro (2013) (17)
The genomic and transcriptional landscape of primary central nervous system lymphoma (2021) (17)
Effects of IFI16 overexpression on the growth and doxorubicin sensitivity of head and neck squamous cell carcinoma–derived cell lines (2007) (17)
Troglitazone-mediated sensitization to TRAIL-induced apoptosis is regulated by proteasome-dependent degradation of FLIP and ERK1/2-dependent phosphorylation of BAD (2008) (17)
AN1-type zinc finger protein 3 (ZFAND3) is a transcriptional regulator that drives Glioblastoma invasion (2020) (17)
Chromogenic in situ Hybridization is a Reliable Alternative to Fluorescence in situ Hybridization for Diagnostic Testing of 1p and 19q Loss in Paraffin‐Embedded Gliomas (2013) (17)
Identification of Ligands and Translation to Clinical Applications (2017) (17)
Glioblastoma initiating cells are sensitive to histone demethylase inhibition due to epigenetic deregulation (2020) (16)
Volumetric assessment of glioblastoma and its predictive value for survival (2019) (16)
Cytotoxic T Cells and their Activation Status are Independent Prognostic Markers in Meningiomas (2019) (16)
Molecular dissection of the valproic acid effects on glioma cells (2016) (16)
Differential genomic and proteomic profiling of glioblastoma cells exposed to terpyridineplatinum(II) complexes. (2009) (16)
Gliosarcoma Is Driven by Alterations in PI3K/Akt, RAS/MAPK Pathways and Characterized by Collagen Gene Expression Signature (2019) (16)
Association Between Tumor Compartment Volumes, the Incidence of Pretreatment Seizures, and Statin-Mediated Protective Effects in Glioblastoma. (2019) (15)
Expression of SGLT-1 in preneoplastic and neoplastic lesions of the head and neck. (2004) (15)
Serum very long-chain fatty acid-containing lipids predict response to immune checkpoint inhibitors in urological cancers (2019) (15)
DNA methylation at an enhancer of the three prime repair exonuclease 2 gene (TREX2) is linked to gene expression and survival in laryngeal cancer (2019) (15)
Quantification of retinoid concentrations in human serum and brain tumor tissues. (2012) (14)
Label-free identification of the glioma stem-like cell fraction using Fourier-transform infrared spectroscopy (2014) (14)
Large-Scale Drug Screening in Patient-Derived IDHmut Glioma Stem Cells Identifies Several Efficient Drugs among FDA-Approved Antineoplastic Agents (2020) (14)
TERT and DNMT1 expression predict sensitivity to decitabine in gliomas. (2020) (13)
Correlated MRI and Ultramicroscopy (MR-UM) of Brain Tumors Reveals Vast Heterogeneity of Tumor Infiltration and Neoangiogenesis in Preclinical Models and Human Disease (2019) (13)
N-Alkyl-1,5-dideoxy-1,5-imino-l-fucitols as fucosidase inhibitors: Synthesis, molecular modelling and activity against cancer cell lines. (2019) (13)
Elimination of undifferentiated cancer cells by pluripotent stem cell inhibitors. (2014) (13)
Retinoid resistance and multifaceted impairment of retinoic acid synthesis in glioblastoma (2015) (13)
Extent of Resection, MGMT Promoter Methylation Status and Tumor Location Independently Predict Progression-Free Survival in Adult Sporadic Pilocytic Astrocytoma (2019) (13)
Heparanase expression in head and neck squamous cell carcinomas is associated with reduced proliferation and improved survival (2011) (12)
Micronucleus formation in human cancer cells is biased by chromosome size (2019) (12)
Oligosarcomas, IDH-mutant are distinct and aggressive (2021) (12)
A fusogenic dengue virus-derived peptide enhances antitumor efficacy of an antibody-ribonuclease fusion protein targeting the EGF receptor. (2014) (12)
A PRDX1‐p38α heterodimer amplifies MET‐driven invasion of IDH‐wildtype and IDH‐mutant gliomas (2018) (12)
Generation of “LYmph Node Derived Antibody Libraries” (LYNDAL) for selecting fully human antibody fragments with therapeutic potential (2013) (11)
Gain of 12p encompassing CCND2 is associated with gemistocytic histology in IDH mutant astrocytomas (2016) (11)
Surfactant Expression Defines an Inflamed Subtype of Lung Adenocarcinoma Brain Metastases that Correlates with Prolonged Survival (2020) (11)
A novel patient stratification strategy to enhance the therapeutic efficacy of dasatinib in glioblastoma. (2021) (11)
Transgene expression by oncolytic adenoviruses is modulated by E1B19K deletion in a cell type-dependent manner. (2009) (11)
Human papilloma virus (HPV) 18 proteins E6 and E7 up-regulate ABC transporters in oropharyngeal carcinoma. Involvement of the nonsense-mediated decay (NMD) pathway. (2018) (10)
Histone epiproteomic profiling distinguishes oligodendroglioma, IDH-mutant and 1p/19q co-deleted from IDH-mutant astrocytoma and reveals less tri-methylation of H3K27 in oligodendrogliomas (2019) (10)
Cellular Pharmacokinetic/Pharmacodynamic Relationship of Platinum Cytostatics in Head and Neck Squamous Cell Carcinoma Evaluated by Liquid Chromatography Coupled to Tandem Mass Spectrometry (2012) (10)
Expression of mRNAs encoding for growth factors, ECM molecules, and MMP13 in mono-cultures and co-cultures of human periodontal ligament fibroblasts and alveolar bone cells (2005) (10)
Cystathionine-γ-lyase drives antioxidant defense in cysteine-restricted IDH1-mutant astrocytomas (2021) (10)
Antibody Responses to Cancer Antigens Identify Patients with a Poor Prognosis among HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinoma Patients (2019) (10)
Optimal Timing of Extracorporeal Shock Wave Treatment to Protect Ischemic Tissue (2011) (9)
Patterns of antibody responses to nonviral cancer antigens in head and neck squamous cell carcinoma patients differ by human papillomavirus status (2019) (9)
Metabolic plasticity of IDH1-mutant glioma cell lines is responsible for low sensitivity to glutaminase inhibition (2020) (9)
Glycodelin as a Serum and Tissue Biomarker for Metastatic and Advanced NSCLC (2018) (9)
Tumor-Specific Regulatory T Cells from the Bone Marrow Orchestrate Antitumor Immunity in Breast Cancer (2019) (9)
An EGF receptor targeting Ranpirnase-diabody fusion protein mediates potent antitumour activity in vitro and in vivo. (2015) (9)
The pregnane X receptor (PXR) and the nuclear receptor corepressor 2 (NCoR2) modulate cell growth in head and neck squamous cell carcinoma (2018) (9)
KIF11 inhibitors filanesib and ispinesib inhibit meningioma growth in vitro and in vivo. (2021) (8)
Helping EGFR inhibition to block cancer (2017) (8)
Molecular profiling-based decision for targeted therapies in IDH wild-type glioblastoma (2020) (8)
Pleomorphic xanthoastrocytoma is a heterogeneous entity with pTERT mutations prognosticating shorter survival (2022) (8)
Molecular Diagnostics in Pediatric Brain Tumors: Impact on Diagnosis and Clinical Decision-Making — A Selected Case Series (2018) (8)
Single-nucleus chromatin accessibility reveals intratumoral epigenetic heterogeneity in IDH1 mutant gliomas (2019) (8)
[Glucose uptake in malignant tumors of the head and neck]. (1999) (7)
Preclinical evaluation of peptide-based radiotracers for integrin αvβ6-positive pancreatic carcinoma (2019) (7)
Radioresistance and transcriptional reprograming of invasive glioblastoma cells. (2021) (7)
Role of NR1I2 (pregnane X receptor) polymorphisms in head and neck squamous cell carcinoma (2015) (7)
Calcitriol Promotes Differentiation of Glioma Stem-Like Cells and Increases Their Susceptibility to Temozolomide (2021) (7)
Cannabidiol converts NF-κB into a tumor suppressor in glioblastoma with defined antioxidative properties (2021) (7)
An effective strategy of human tumor vaccine modification by coupling bispecific costimulatory molecules (1999) (7)
The anesthetist’s choice of inhalational vs. intravenous anesthetics has no impact on survival of glioblastoma patients (2020) (7)
Combined Treatment of ATRA with Epigenetic Drugs Increases Aggressiveness of Glioma Xenografts. (2016) (7)
Microenvironment and brain tumor stem cell maintenance: impact of the niche. (2014) (7)
Cortactin expression: Association with disease progression and survival in oral squamous cell carcinoma (2018) (6)
Chronophin regulates active vitamin B6 levels and transcriptomic features of glioblastoma cell lines cultured under non-adherent, serum-free conditions (2018) (6)
Cysteine is a limiting factor for glioma proliferation and survival (2021) (6)
[Functional expression of vascular endothelial growth factor receptor Flt-1 on squamous cell carcinoma of the head and neck]. (1999) (6)
Antiproliferative efficacies but minor drug transporter inducing effects of paclitaxel, cisplatin, or 5-fluorouracil in a murine xenograft model for head and neck squamous cell carcinoma (2014) (6)
Chordoid meningiomas can be sub-stratified into prognostically distinct DNA methylation classes and are enriched for heterozygous deletions of chromosomal arm 2p (2018) (6)
Temozolomide-Induced RNA Interactome Uncovers Novel LncRNA Regulatory Loops in Glioblastoma (2020) (6)
A connectivity signature for glioblastoma (2021) (6)
Prognostic Value of microRNA-221/2 and 17-92 Families in Primary Glioblastoma Patients Treated with Postoperative Radiotherapy (2021) (6)
Umbrella protocol for phase I/IIa trials of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed glioblastoma without MGMT promoter methylation Neuro Master Match (N²M²). (2016) (5)
Functional role of miR-148a in oropharyngeal cancer: influence on pregnane X receptor and P-glycoprotein expression (2019) (5)
Impact of post-surgical freezing delay on brain tumor metabolomics (2019) (5)
STAT3 Enhances Sensitivity of Glioblastoma to Drug-Induced Autophagy-Dependent Cell Death (2022) (5)
Integration and Comparison of Transcriptomic and Proteomic Data for Meningioma (2020) (5)
[Prognosis of brain tumors: epidemiology, survival time and clinical course]. (1998) (5)
Rapid-CNS2: rapid comprehensive adaptive nanopore-sequencing of CNS tumors, a proof-of-concept study (2022) (5)
XAB2 promotes Ku eviction from single-ended DNA double-strand breaks independently of the ATM kinase (2021) (5)
Abstract 2396: IMA950: A novel multi-peptide cancer vaccine for treatment of glioblastoma (2010) (5)
Nuclei Isolation from Fresh Frozen Brain Tumors for Single-Nucleus RNA-seq and ATAC-seq. (2020) (5)
A New Pentafluorothio-Substituted Curcuminoid with Superior Antitumor Activity (2021) (5)
[Expression and localization profile of tenascin in squamous cell carcinomas of the head and neck]. (1999) (5)
VXM01 phase I study in patients with progressive glioblastoma: Final results. (2018) (4)
Non-invasive glioblastoma immunoprofiling by printed peptide arrays (2016) (4)
Integrated Metabolomics and Transcriptomics Analysis of Monolayer and Neurospheres from Established Glioblastoma Cell Lines (2021) (4)
Integrated phospho-proteogenomic and single-cell transcriptomic analysis of meningiomas establishes robust subtyping and reveals subtype-specific immune invasion (2021) (4)
Glioma Cells Differentiation Therapy Exerts Antitumor Effects on Stem-like Updated (2010) (3)
Lessons we learned from high-throughput and top-down systems biology analyses about glioma stem cells. (2014) (3)
RhoA regulates translation of the Nogo-A decoy SPARC in white matter-invading glioblastomas (2019) (3)
Supplemental Information New Brain Tumor Entities Emerge from Molecular Classi fi cation of CNS-PNETs (2016) (3)
An Observational Cohort Study on 194 Supraglottic Cancer Patients: Implications for Laser Surgery and Adjuvant Treatment (2021) (3)
[Significance of aberrant p53 protein in head-neck tumors and its effect on proliferation and differentiation]. (1993) (3)
Increased Radiation-Associated T-Cell Infiltration in Recurrent IDH-Mutant Glioma (2020) (3)
Glioblastoma evolution pattern under surgery and radio(chemo)therapy (RCHT) to identify novel methylome based glioma subtypes. (2019) (3)
IMPS-14PROGNOSTIC ROLE OF REGULATORY T-CELLS IN PRIMARY AND RECURRENT MENINGIOMA. (2015) (3)
Receptor-Tyrosine Kinase Inhibitor Ponatinib Inhibits Meningioma Growth In Vitro and In Vivo (2021) (3)
Polyethylenimine, an Autophagy-Inducing Platinum-Carbene-Based Drug Carrier with Potent Toxicity towards Glioblastoma Cancer Stem Cells (2022) (2)
Could Primary Chemoradiotherapy in T2 Glottic Cancers Yield Results Comparable to Primary Radiotherapy in T1? Considerations from 531 German Early Stage Patients (2021) (2)
Accuracy of high-risk HPV DNA PCR, p16(INK4a) immunohistochemistry or the combination of both to diagnose HPV-driven oropharyngeal cancer (2021) (2)
Whole Blood Transcriptional Fingerprints of High-Grade Glioma and Longitudinal Tumor Evolution under Carbon Ion Radiotherapy (2022) (2)
An N-heterocyclic carbene iridium(III) complex as a potent anti-cancer stem cell therapeutic. (2022) (2)
Discovery of a reliable and robust methylome classifier of HPV driven head and neck cancer with favorable response to chemoradiation: A multicenter study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). (2018) (2)
ANGI-02. INHIBITION OF APLN-APLNR SIGNALLING BLOCKS TUMOUR ANGIOGENESIS AND ATTENUATES INVASIVE GLIOBLASTOMA GROWTH (2017) (2)
SPONTANEOUS IMMUNE RESPONSES IN GBM PATIENTS AFTER COMPLETE TUMOR RESECTION ARE ASSOCIATED WITH AN IMPROVED SURVIVAL (2014) (2)
Rapid-CNS2: Rapid comprehensive adaptive nanopore-sequencing of CNS tumors, a proof of concept study (2021) (2)
Analysis of CIC‐associated CpG island methylation in oligoastrocytoma (2013) (2)
SPOT-006 Stem cell-associated heterogeneity in glioblastoma is a result of intrinsic tumour plasticity shaped by the microenvironment (2018) (2)
VXM01 phase I study in patients with resectable progression of a glioblastoma. (2017) (2)
Gold(I) complexes based on six-membered phosphorus heterocycles as bio-active molecules against brain cancer. (2020) (2)
Chemoradiotherapy but Not Radiotherapy Alone for Larynx Preservation in T3. Considerations from a German Observational Cohort Study (2021) (1)
P04.22OLIGOASTROCYTOMA DOES NOT EXIST: A MOLECULAR GENETIC REAPPRAISAL ON SINGLE-CELL LEVEL (2014) (1)
P01.133 Preoperative predictors of malignancy in non-enhancing glioma in the era of molecular classification (2018) (1)
Connective tissue growth factor (CTGF) methylation status is associated with prognosis of patients with head and neck squamous cell carcinoma (HNSCC) treated with radiochemotherapy (RCHT): A multicenter study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). (2019) (1)
Stem cell-associated heterogeneity in Glioblastoma results from intrinsic tumor plasticity shaped by the microenvironment (2019) (1)
The pregnane X receptor ( PXR ) and the nuclear receptor corepressor 2 ( NCoR 2 ) modulate cell growth in head and neck squamous cell carcinoma (2018) (1)
Integrated metabolomics and transcriptomics analysis of monolayer and neurospheres from glioblastoma cells (2020) (1)
Correction: Gold(I) complexes based on six-membered phosphorus heterocycles as bio-active molecules against brain cancer. (2020) (1)
ATIM-35. VXM01 PHASE I STUDY IN PATIENTS WITH PROGRESSIVE GLIOBLASTOMA – FINAL RESULTS (2018) (1)
Elimination of CD 133 þ Tumor Cells with Targeted Oncolytic Measles Virus (2013) (1)
Abstract 3240: The Wnt secretion factor Evi/Wls/Gpr177 promotes glioma tumorigenesis (2012) (1)
Comparative Study of the Novel RGD Motif-containing αvβ6 Integrin Binding Peptides SFLAP3 and SFITGv6 for Diagnostic Application in HNSCC (2018) (1)
P07.04 Rapid-CNS2: Rapid comprehensive adaptive nanopore-sequencing of CNS tumors, a proof of concept study (2021) (1)
OS1.2 Effects of the IDH1R132H mutation on redox-status and metabolism are cell type dependent but independent from D-2-hydroxyglutarate accumulation (2016) (1)
BH3 mimetics targeting BCL-XL impact the senescent compartment of pilocytic astrocytoma. (2022) (1)
Human Leucocyte Antigens as Prognostic Markers in Head and Neck Squamous Cell Carcinoma (2022) (1)
Luminescent Pyrrole-Based Phosphaphenalene Gold Complexes: Versatile Anticancer Tools with Wide Applicability. (2022) (1)
Pharmacological Landscape of FDA-approved Anticancer Drugs Reveals Sensitivities to Ixabepilone, Romidepsin, Omacetaxine, and Carfilzomib in Aggressive Meningiomas. (2022) (1)
NIMG-02. NON-INVASIVE DETECTION OF IDH MUTANT 1p19q NON-CODELETED GLIOMAS USING THE T2-FLAIR MISMATCH SIGN (2019) (1)
Anaplastic ganglioglioma—A diagnosis comprising several distinct tumour types (2022) (1)
Photon Versus Proton Versus Carbon Irradiation of Glioma Initiating Cells (2012) (1)
NIMG-30. PREOPERATIVE PREDICTORS OF MALIGNANCY IN NON-ENHANCING GLIOMA IN THE ERA OF MOLECULAR CLASSIFICATION (2018) (1)
OMICS AND PROGNSTIC MARKERS (2013) (1)
Luminescent Pyrrole‐Based Phosphaphenalene Gold Complexes: Versatile Anticancer Tools with Wide Applicability (2022) (1)
Single-cell DNA sequencing reveals order of mutational acquisition in TRAF7/AKT1 and TRAF7/KLF4 mutant meningiomas (2022) (1)
PD-L1-R: A MR based surrogate for PD-L1 expression in Glioblastoma multiforme. (2021) (1)
GENE-12. ANAPLASTIC NEUROEPITHELIAL TUMOR WITH CONDENSED NUCLEI (ANTCON): A NOVEL BRAIN TUMOR ENTITY WITH RECURRENT NTRK FUSION (2019) (1)
TMOD-08. PRIMARY AND RECURRENT GLIOMA PATIENT-DERIVED ORTHOTOPIC XENOGRAFTS (PDOX) REPRESENT RELEVANT PATIENT AVATARS FOR PRECISION MEDICINE (2020) (1)
P09.09 Gain of 12p encompassing CCND2 is associated with gemistocytic histology in IDH mutant astrocytomas (2016) (0)
Combining organotypic tissue culture with multi-color fluorescence light-sheet microscopy (OTCxLSFM) – a novel tool to study glioma invasion/migration (2023) (0)
PATH-23. OLIGOSARCOMA, IDH-MUTANT IS A DISTINCT AGGRESSIVE TYPE (2021) (0)
Chemotherapy with BCNU in recurrent glioma: Analysis of clinical outcome and side effects in chemotherapy-naïve patients (2016) (0)
The impact of tumor metabolic activity assessed by 18F-FET amino acid PET imaging in particle radiotherapy of high-grade glioma patients (2022) (0)
P29 The role of HPV in cervical lymph node metastases from squamous cell carcinoma (2015) (0)
OS3.6 Development and validation of a DNA methylome-based predictor of meningioma recurrence and meningioma recurrence score (2018) (0)
Title : IDH 1 Mutations Induce Organelle Defects Via Dysregulated Phospholipids 1 (2020) (0)
HIP1R and Vimentin immunohistochemistry predict 1p/19q status in IDH-mutant glioma. (2022) (0)
Om-050. Identification Of Prognostic Serum-antibodies Against Glioblastoma-associated Antigens (2013) (0)
Crystal Structure Analysis of the human Glutahione Reductase, complexed with GoPI (2006) (0)
DDIS-21. KIF11 INHIBITORS FILANESIB AND ISPINESIB AS NOVEL AGENTS FOR MENINGIOMA THERAPY (2018) (0)
Tumor stem cells in gliomas – clinical impact of the stem cell marker CD133 and therapeutical strategies (2008) (0)
MODL-04. ESTABLISHMENT OF A RELIABLE GLIOBLASTOMA TUMOR-ORGANOID PLATFORM ENABLES AUTOMATED HIGH-THROUGHPUT DRUG SCREENING ADVANCING PERSONALIZED MEDICINE (2022) (0)
292 T-cell based identification of tissue antigens by automated two-dimensional protein fractionation (2010) (0)
TAMI-61. TUMOR-ASSOCIATED MACROPHAGES ARE INDEPENDENT PROGNOSTIC MARKERS IN MENINGIOMAS (2020) (0)
Identification of a specific head and neck carcinoma binding peptide (2006) (0)
Evaluation of the Cytotoxicity of Cationic Polymers on Glioblastoma Cancer Stem Cells (2022) (0)
GE-30OLIGOASTROCYTOMA DOES NOT EXIST: IN-SITU MOLECULAR GENETICS FAVORS CLASSIFICATION AS EITHER OLIGODENDROGLIOMA OR ASTROCYTOMA (2014) (0)
424 Aberrant retinoic acid signaling in astrocytic gliomas (2010) (0)
CBIO-20. HIGH LEVELS OF TERT CONFER SENSITIVITY TO THE DNA HYPOMETHYLATING AGENT DECITABINE (DAC) IN GLIOMAS (2021) (0)
360: Reduced promoter methylation and increased expression of CSPG4 negatively influences survival of HNSCC patients (2014) (0)
O-9-124 Influence of tumorangiogenesis on extracellular matrix composition in malignant gliomas (1997) (0)
P04.18 Heterogeneity and plasticity of integrin α5β1 expression in glioblastoma stem cells (2021) (0)
P01.031 VXM01 phase I study in patients with progressive glioblastoma - final results (2018) (0)
Neutralization of the effect of CD95 to block the invasion of glioblastoma cells in vivo (2007) (0)
LGG-18. Inhibition of Bcl-xL targets the senescent compartment of pilocytic astrocytoma (2022) (0)
LAB-STEM CELLS (2012) (0)
DDIS-34. HIGH-THROUGHPUT DRUG SCREENING OF FDA-APPROVED ANTINEOPLASTIC DRUGS FOR THE TREATMENT OF AGGRESSIVE MENINGIOMAS (2019) (0)
CBMT-42. LOSS OF PROMOTER METHYLATION IN GLYCOLYTIC GENES IS ASSOCIATED WITH AGGRESSIVENESS IN IDH1-MUTANT LOWER GRADE GLIOMAS (2018) (0)
P01.106 Impact of intraoperative magnetic resonance imaging on the extent of resection and functional outcome in awake surgery for eloquent gliomas - a single center retrospective study (2018) (0)
IMMU-49. CYTOTOXIC T CELLS AND THEIR ACTIVATION STATUS ARE INDEPENDENT PROGNOSTIC MARKERS IN MENINGIOMAS (2018) (0)
MODL-04. Drug screening in Disorders with Abnormal DNA Damage Response/Repair (DADDR) andin vivo validation (2022) (0)
9 Proffered Paper: Identification and Evaluation of Tumor Associated Antigens in Head and Neck Patients (2012) (0)
SURG-19. IMPACT OF INTRAOPERATIVE MAGNETIC RESONANCE IMAGING ON THE EXTENT OF RESECTION AND FUNCTIONAL OUTCOME IN AWAKE SURGERY FOR ELOQUENT GLIOMAS – A SINGLE CENTER RETROSPECTIVE STUDY (2018) (0)
Identi ﬁ cation of a Novel ITG a v b 6 -Binding Peptide Using Protein Separation and Phage Display (2017) (0)
Diagnostic potential of extracellular vesicles in meningioma patients. (2022) (0)
8707 POSTER Expression and Regulation of AC133 and CD133 in Glioblastoma (2011) (0)
Glioneuronal tumor with ATRX alteration, kinase fusion and anaplastic features (GTAKA): a molecularly distinct brain tumor type with recurrent NTRK gene fusions (2023) (0)
[Larynx preservation up to T4 laryngeal cancer?] (2022) (0)
P04.79 Cytotoxic T cells and their activation status are independent prognostic markers in meningiomas (2018) (0)
Chronophin regulates active vitamin B6 levels and transcriptomic features of glioblastoma cell lines cultured under non-adherent, serum-free conditions (2018) (0)
Recurrent MET fusion genes represent a druggable target in paediatric glioblastoma 1 2 (2016) (0)
A Transcriptional Fingerprint of Carbon Ion Radiotherapy in Patients with Recurrent Glioma Utilizing Peripheral Blood as a Sentinel Organ (2019) (0)
ANGI-03. PHARMACOLOGICAL TARGETING OF APELIN/APLNR SIGNALING BLUNTS THERAPY RESISTANCE TO VEGFA/VEGFR2 ANTI-ANGIOGENIC TREATMENT IN GLIOBLASTOMA (2019) (0)
IMMU-07. REPROGRAMMING OF MICROGLIA/MACROPHAGES IN GLIOBLASTOMA IMPROVES ANTI-TUMOR T CELL RESPONSES (2021) (0)
Cell culture models of pediatric high-grade glioma are susceptible to parvovirus-1 induced cytotoxicity (2013) (0)
XAB2 prevents abortive recombinational repair of replication-associated DNA double-strand breaks and its loss is synthetic lethal with RAD52 inhibition (2020) (0)
Anaplastic pilocytic astrocytoma-an IDH-wildtype diffuse glioma characterized by a distinct DNA methylation profile and combined alterations in MAPK pathway genes, CDKN2A/B and ATRX (2017) (0)
CHRDL1 Regulates Stemness in Glioma Stem-like Cells (2022) (0)
O6.06PERIPHERAL T CELL RESPONSES IN GLIOBLASTOMA PATIENTS ARE ASSOCIATED WITH AN IMPROVED SURVIVAL (2014) (0)
MODL-35. A NOVEL PATIENT-DERIVED TUMOR ORGANOID MODEL IDENTIFIES HDACI PANOBINOSTAT AS HIGHLY EFFECTIVE DRUG IN MENINGIOMAS (2022) (0)
A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma (2022) (0)
355 Clonogenicity and in Vivo Growth Identify Two Types of Stem-like Glioblastoma Cells (SLGC) Differing in Tumorigenicity and Invasiveness (2012) (0)
Neutralizing activity of CD95 blocking the invasion of glioblastoma cells in vivo (2007) (0)
Impact of post-surgical freezing delay on brain tumor metabolomics (2019) (0)
Tumor antigen specific Treg from the bone marrow migrate towards increased S1P and CCL2 gradients established in the blood of breast cancer patients (2016) (0)
JS08.6.A A connectivity signature for glioblastoma (2022) (0)
Rapid detection of 2-hydroxyglutarate in frozen sections of IDH mutant tumors by MALDI-TOF mass spectrometry (2018) (0)
DDRE-28. IDENTIFICATION OF SYNERGISTIC DRUG COMBINATIONS FOR THE THERAPY OF IDHmut GLIOMA (2021) (0)
CSIG-07. SIMULTANEOUS EXPLORATION OF A SET OF PRECLINICAL GBM-MODELS PROVIDES PREDICTIVE DATA ON CLINICALLY RELEVANT DRUGS (2016) (0)
MNGI-01. KIF11 AS A NOVEL THERAPEUTIC TARGET IN MENINGIOMA (2017) (0)
P09.18 Location-dependent prognostic factors and recurrence patterns in IDH wildtype glioblastoma. (2017) (0)
EXTH-63. IN VITRO DRUG SCREENING BASED ON IN SILICO DATA IDENTIFIES NEW THERAPEUTIC AGENTS FOR AGGRESSIVE MENINGIOMA (2020) (0)
Glioma Patients: Role of CD133 Stem Cell Antigen (2012) (0)
P01.07 Identification of novel molecular targets for TMZ-based therapies against glioblastoma: A comprehensive shRNA-based screen of DNA Damage Response factors (2016) (0)
IMST-34. IMMUNOLOGICAL CHANGES DURING TUMOR PROGRESSION FROM PRIMARY TO RECURRENT GLIOBLASTOMA (2016) (0)
ANGI-02. GENOME-WIDE shRNA SCREEN IDENTIFIES CANDIDATE GENES DRIVING GLIOBLASTOMA INVASION (2019) (0)
MAPK pathway activation in low-grade astrocytomas by BRAF gene duplications and activating mutations (2008) (0)
Proffered Paper: Immunological changes during tumor progression from primary to recurrent glioblastoma (2016) (0)
[Larynx preservation: recommendations for decision-making in T3 laryngeal cancer patients]. (2022) (0)
Expression and localization of bullous pemphigoid antigen and a6/b4 integrins discriminates between invasive and metastatic capacity of squamous cell carcinomas (2007) (0)
MR Intensity Normalization Methods Impact Sequence Specific Radiomics Prognostic Model Performance in Primary and Recurrent High-Grade Glioma (2023) (0)
Abstract 2896: Identification of novel tumor associated antigens in colorectal cancer (2014) (0)
Structure analysis and binding properties of HBP-1, a HNSSC specific peptide (2008) (0)
Role of NR1I2 (pregnane X receptor) polymorphisms in head and neck squamous cell carcinoma (2015) (0)
The Antiepileptic Drug Oxcarbazepine Inhibits the Growth of Patient-Derived Isocitrate Dehydrogenase Mutant Glioma Stem-like Cells (2023) (0)
STMC-14. GLIOBLASTOMA CANCER STEM CELLS UNDERGO DYNAMIC STATE TRANSITIONS (2016) (0)
Parvovirus H-1 (H-1PV) exerts oncolytic effects in cell culture models of human brain tumor-initiating cells (2012) (0)
Valproic acid sensitizes glioma cell lines to temozolomide and decreases proliferation (2016) (0)
Primary and recurrent glioma patient-derived orthotopic xenografts (PDOX) represent relevant patient avatars for precision medicine (2020) (0)
extent of resection in supratentoria l WHO JUDGH,,DVWURF\WRPDVVWUDWLøHGIRU,'+PXWDWLRQVWDWXV a single-center volumetric analysis (2016) (0)
High‐Complexity cellular barcoding and clonal tracing reveals stochastic and deterministic parameters of radiation resistance (2021) (0)
Emigration of tumor specific regulatory T cells from the bone marrow is triggered by S1P1 and correlates with their accumulation in breast tumors (TUM9P.1001) (2015) (0)
Development and Validation of an Individualized Predictor of Meningioma Recurrence: A Multicenter Retrospective Cohort Study (2019) (0)
Towards a molecular algorithm predicting glioma treatment response and resistance: A biomarker analysis and path to real time profiling in N2M2. (2018) (0)
OS6.4 Molecular classification of meningiomas across all histological subtypes and grades (2016) (0)
Rare BRAF mutations distinguish anorectal from cutaneous melanoma (2004) (0)
Sphingosine-1-Phosphate Recruits Macrophages and Microglia and Induces a Pro-Tumorigenic Phenotype That Favors Glioma Progression (2023) (0)
DDIS-22. DRUG SCREEN IN PATIENT-DERIVED IDHMUT GLIOMA STEM CELLS IDENTIFIES SEVERAL FDA-APPROVED ANTINEOPLASTIC AGENTS (2019) (0)
IMMU-22. REPROGRAMMING OF MICROGLIA/MACROPHAGES IN GLIOBLASTOMA IMPROVES ANTI-TUMOR T CELL RESPONSES (2022) (0)
SURG-16PROGNOSTIC VALUE OF THE EXTENT OF RESECTION AND IDH1 MUTATION STATUS IN WHO GRADE II ASTROCYTOMAS (2015) (0)
MR-Class: A Python Tool for Brain MR Image Classification Utilizing One-vs-All DCNNs to Deal with the Open-Set Recognition Problem (2023) (0)
TMIC-09. EXPRESSION ANALYSIS OF IDH1 WILD-TYPE AND MUTANT GLIOMA STEM CELLS UNDER HYPOXIA IDENTIFIES NOVEL SURVIVAL-ASSOCIATED GENES IN GLIOBLASTOMA PATIENTS (2016) (0)
P11.59 Integrin a5 heterogeneous expression in glioblastoma is related to glioma stem cell subpopulations (2019) (0)
FSMP-07. CYSTATHIONINE-Γ-LYASE DRIVES ANTIOXIDANT DEFENSE IN CYSTEINE-RESTRICTED IDH1 MUTANT ASTROCYTOMAS (2021) (0)
MNGI-14. LOSS OF HISTONE H3K27me3 IDENTIFIES A SUBSET OF MENINGIOMAS WITH INCREASED RISK OF RECURRENCE (2018) (0)
Oncolytic Measles Virus Tumor Cells with Targeted + Specific Elimination of CD 133 Updated (2013) (0)
Metabolic biomarkers of radiotherapy response in plasma and tissue of an IDH1 mutant astrocytoma mouse model (2022) (0)
DDIS-35. RelA-ACTIVITY IS ESSENTIAL FOR CANNABIDIOL-MEDIATED CYTOTOXICITY IN AN IDENTIFIED SUBSET OF GLIOBLASTOMA (2019) (0)
P05.01 Patient-derived xenograft (PDX) model of glioblastoma: from basic research to preclinical studies (2016) (0)
Glioma Through the Looking GLASS: the Glioma Longitudinal Analysis consortium, molecular evolution of diffuse gliomas (2017) (0)
Single-nucleus chromatin accessibility reveals intratumoral epigenetic heterogeneity in IDH1 mutant gliomas (2019) (0)
QOLP-22. THE PSYCHO-ONCOLOGICAL BURDEN OF PATIENTS WITH AGGRESSIVE MENINGIOMA – RESULTS FROM A RETROSPECTIVE CROSS-SECTIONAL STUDY (2021) (0)
BIOM-39. METHYLATION AND MUTATION PROFILES IN MENINGIOMA CELL-DERIVED EXTRACELLULAR VESICLE DNA REFLECT EPIGENETIC AND GENOMIC ALTERATIONS IN ORIGINAL TUMORS (2021) (0)
DNA-Methylome based Tumor Hypoxia Classifier Identifies HPV-negative Head & Neck Cancer Patients at Risk for Locoregional Recurrence After Primary Radiochemotherapy. (2023) (0)
MBRS-12. INTERFERENCE WITH THE FUNCTION OF MYC IN GROUP 3 MEDULLOBLASTOMA (2018) (0)
Development of a GBM vaccine based on HLA-A2-associated peptides (2012) (0)
Endothelial Indoleamine-2,3-Dioxygenase-1 is not Critically Involved in Regulating Antitumor Immunity in the Central Nervous System (2023) (0)
Abstract LB-308: Effects of the IDH1 R132H mutation on redox status and metabolism are cell type dependent but independent from D-2-hydroxyglutarate accumulation (2016) (0)
Umbrella protocol for phase I/IIa trials of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed glioblastoma without MGMT promoter methylation Neuro Master Match (N{superscript 2}M{superscript 2}). (2016) (0)
Abstract 1105: Carbon ion radiotherapy eradicates glioblastoma via tumor immune environment reprograming (2023) (0)
Hypoxia Methylome Classifier (HDMC) Outperforms Gene Signatures in Identifying HPV-Negative HNSCC Patients at Risk for Locoregional Failure Post Primary Radiochemotherapy: A German Cancer Consortium Radiation Oncology Group (DKTK-ROG) Multicenter Trial (2020) (0)
P04.04 Optimizing dasatinib for glioblastoma treatment (2021) (0)
Metabolic plasticity of IDH1-mutant glioma cell lines is responsible for low sensitivity to glutaminase inhibition (2020) (0)
PFKFB4 interacts with FBXO28 to promote HIF-1α signaling in glioblastoma (2022) (0)
Tumors diagnosed as cerebellar glioblastoma comprise distinct molecular entities (2019) (0)
P-3-236 Autocrine growth stimulation of malignant gliomas by the hematopoietic growth factors G-CSF and GM-GSF (1997) (0)
PL3.4 Intrinsic tumor plasticity in Glioblastoma allows for recreation of stem like-states and efficient tumor cell adaptation to new microenvironments (2019) (0)
High complexity cellular barcoding and clonal tracing reveals stochastic and deterministic parameters of radiation resistance (2020) (0)
Boron- and phosphorus-containing molecular/nano platforms: exploiting pathological redox imbalance to fight cancer. (2022) (0)
Risk Estimation in Non-Enhancing Glioma: Introducing a Clinical Score (2023) (0)
P12.12.A Resolving the cellular architecture of infiltration zones in glioblastoma (2022) (0)
Glioblastoma cancer stem cells: Adaptive or stable phenotype? (2016) (0)
DNA methylation at an enhancer of the three prime repair exonuclease 2 gene (TREX2) is linked to gene expression and survival in laryngeal cancer (2019) (0)
Abstract 4032: Consequences ofNEIL1promoter hypermethylation in head and neck squamous cell carcinoma (2012) (0)
DNA-methylome-assisted classification of patients with poor prognostic subventricular zone associated IDH-wildtype glioblastoma (2022) (0)
Isocitrate-dehydrogenase-mutant lower grade glioma in elderly patients: treatment and outcome in a molecularly characterized contemporary cohort (2023) (0)
Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate (2018) (0)
892: Peripheral T cell responses in glioblastoma patients are associated with an improved survival (2014) (0)
Reprogramming M2-polarized patient-derived glioblastoma associated microglia/macrophages via CSF1R inhibition (2022) (0)
Endothelial Cells Derived from Non-malignant Tissues Are of Limited Value as Models for Brain Tumor Vasculature. (2015) (0)
P11.26 Genome-wide shRNA screen identifies candidate genes driving glioblastoma invasion (2019) (0)
Pleomorphic xanthoastrocytoma is a heterogeneous entity with pTERT mutations prognosticating shorter survival (2022) (0)
MNGI-05. DEVELOPMENT AND VALIDATION OF A DNA METHYLOME-BASED PREDICTOR OF MENINGIOMA RECURRENCE AND MENINGIOMA RECURRENCE SCORE (2018) (0)
STEM-09. INTRINSIC TUMOR PLASTICITY IN GLIOBLASTOMA ALLOWS FOR RECREATION OF STEM LIKE-STATES AND EFFICIENT TUMOR CELL ADAPTATION TO NEW MICROENVIRONMENTS (2019) (0)
DDRE-30. HIGH-THROUGHPUT DRUG SCREENING OF FDA-APPROVED ANTINEOPLASTIC DRUGS FOR THE TREATMENT OF AGGRESSIVE MENINGIOMAS (2020) (0)
DRES-05. MOLECULAR EVOLUTION OF DIFFUSE GLIOMAS AND THE GLIOMA LONGITUDINAL ANALYSIS CONSORTIUM (2018) (0)
Intraventricular meningiomas frequently harbor NF2 mutations but lack common genetic alterations in TRAF7, AKT1, SMO, KLF4, PIK3CA, and TERT (2019) (0)
Results Expression of Active Caspase-3 in Brain Tumors In vivo (2007) (0)
Chirasani et al Suppl. Fig 1-5 (2013) (0)
NCOG-25. REVISITING THE PIGNATTI RISK SCORE IN LOW-GRADE GLIOMA PATIENTS IN THE MOLECULAR ERA (2021) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Christel C. Herold‐mende?

Christel C. Herold‐mende is affiliated with the following schools:

Heidelberg University

Christel C. Herold‐mende's Academic­Influence.com Rankings

Why Is Christel C. Herold‐mende Influential?

Christel C. Herold‐mende's Published Works

Published Works

What Schools Are Affiliated With Christel C. Herold‐mende?

Christel C. Herold‐mende's AcademicInfluence.com Rankings